Gilead’s investigational GS-5806 reduces viral load and clinical symptoms in Phase 2 respiratory syncytial virus (RSV) challenge study in adults

21-05-2014 Business Wire HealthComments (0)

BiologyBiotechnologyGilead SciencesHealth Medical PharmaHealth Medical PharmaMononegaviralesPharmaceuticalUSAViral diseases

Gilead Sciences (Nasdaq: GILD) today announced results from a placebo-controlled, Phase 2a challenge study in healthy adult patients intranasally infected with respiratory syncytial virus (RSV). The study of GS-5806, an investigational oral RSV fusion inhibitor, achieved its primary and secondary endpoints of lower viral load (the amount of virus detected in the nasal wash), improvements in total mucus weight (the amount of mucus produced by the nose) and also

Read more on Business Wire Health

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top